A phase II study of ifosfamide and bleomycin in advanced or recurrent cervical carcinoma

Highley, Martin; Samandas, N.; Ziras, N.; Morgan, M.; Hill, M.; Stein, Robert; Barker, Stewart; Coleman, R.; Blake, P R; Morris, DavidL.; Ml, Slevin; Wiltshaw, E.; Harper, P.

doi:10.1046/j.1525-1438.1996.06040323.x

Cited by 1 publication

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among 11 previously untreated patients with cervical cancer given full dose of bleomycin, two had SD, but nine patients had progressive disease on treatment (12) . In a recent phase II study of ifosfamide and bleomycin in cervical cancer, the results suggested that the addition of bleomycin only added to the toxicity without contribution to the activity of ifosfamide (13) . There is also no evidence that in neoadjuvant trials, the addition of bleomycin results in higher response rates (see Table 3).…”

Section: Discussionmentioning

confidence: 99%

Neoadjuvant cisplatin plus ifosfamide in patients with stage IIB cervical cancer: a single center phase II study

Jonge¹,

Falkson²,

Burger³

et al. 1997

Int J Gynecol Cancer

View full text Add to dashboard Cite

The objective of this study was to evaluate cisplatin plus ifosfamide as neoadjuvant chemotherapy with regard to toxicity and clinical response in patients with stage IIB cervical cancer. Sixty‐eight patients with previously untreated stage IIB cervical cancer were given two cycles of chemotherapy: cisplatin 20 mg m−2 on Days 1–5, infused over 1 h; ifosfamide 1.2 g m−2 on Days 1–5 infused over 30 min. Mesna 120 mg m−2 was administered as a bolus 15 min before ifosfamide, and a continuous infusion, delivering Mesna 1.2 g m−2, was given subsequently over the next 16 hours. The treatment cycle was repeated on day 21. Responders were then randomized to surgery or radiation therapy. All 68 patients were evaluable for toxicity. Toxicity was found to be acceptable. One patient died at home one month after completion of the second treatment cycle. There was one grade 4 thrombocytopenia. Grade 3 toxicities included anemia in four patients, leucopenia and nausea and vomiting in one patient each. Sixty‐two patients were evaluable for response. A clinical response was documented in 44 of the 55 evaluable patients (80%), with 17 complete responses (31%) and 27 partial responses (49%) (95% confidence limits 69%–91%, 19%–43%, and 36%–62% respectively). The intent‐to‐treat response rate was 64.7%. Twenty‐one patients were randomized to surgery and 23 patients to radiation therapy. Amongst the eight patients with a complete clinical response, one patient had a complete pathological response and one patient had residual intra‐epithelial neoplasia. The drug combination of cisplatin plus ifosfamide had acceptable toxicity and gave a clinical response rate of 80% in previously untreated patients with stage IIB cervical cancer.

show abstract

Section: Discussionmentioning

confidence: 99%